This activity is intended for primary care clinicians, neurologists, and other specialists who care for adolescents with chronic daily headache.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 200 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/06. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity. AAFP credit is subject to change based on topic selection throughout the accreditation year.
This Activity is sponsored by Medscape Continuing Education Provider Unit.
Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Approved for 0.25 contact hour(s) of continuing nursing education for
RNs and APNs; None of these credits is in the area of pharmacology.
Provider Number: 6FDKKC-PRV-05
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CME / CE Released: 4/30/2007; Reviewed and Renewed: 4/29/2008
Valid for credit through: 4/29/2009, 11:59 PM EST
processing....
April 30, 2007 -- Young adolescents with chronic daily headache (CDH), particularly those who have migraines with aura, are at 6 times greater risk for suicide than their headache-free peers, new research suggests.
"Teens with chronic daily headache should be screened for psychiatric disorders so they can get the treatment and help they need," said study author Shuu-Jiun Wang, MD, in a statement from the American Academy of Neurology.
The community-based study conducted by investigators at the Taipei Veterans General Hospital and National Yang-Ming University School of Medicine in Taipei, Taiwan, included 7900 adolescents aged 12 to 14 years from 5 schools in Taipei.
The study is published in the May 1 issue of Neurology.
Students were surveyed and those who reported frequent headaches were referred to a neurologist for diagnosis of headache subtype. A total of 122 subjects with CDH were identified.
CDH was defined as 15 or more headache days per month for more than 3 months, with each headache lasting 2 hours or more daily.
Following diagnosis of CDH subtype, a psychiatrist, who was blinded to students' subtype status, screened subjects for current comorbid psychiatric disorders including depression and various types of anxiety disorders using the Mini-International Neuropsychiatric Interview-Kid (MINI-Kid) for children and adolescents.
Adolescents were also screened for current suicide risk using the MINI Suicidality Module. Subjects were considered at high suicide risk if they had a score of 10 or greater. A total of 121 individuals completed the in-person interviews.
Almost half of subjects had at least 1 psychiatric disorder. Major depression (21%) and panic disorder (19%) were the 2 most frequent diagnoses. Investigators also found 20% of subjects were at high risk for suicide.
According to Dr. Wang, these numbers are much higher than those in recently reported data among Taiwan's general teen population.
Individuals with migraine headaches were 3.5 times more likely to have a psychiatric disorder than those without migraine. In addition, the investigators found those who had migraine with aura were at even greater risk for psychiatric disorders and higher suicide risk.
According to the authors, the study's revelation that migraine with aura is linked to higher risk for psychiatric comorbidities and suicide risk is notable.
"Intriguingly, migraine with aura has seldom been raised as an issue in patients with CDH since most headache experts believe that patients with chronic migraine usually have migraine without aura," they write.
Of the total study group, 81 (67%) had migraine or probable migraine and, of these, 67 (55%) had migraine without aura and 14 (12%) had migraine with and without aura.
Age and sex effects were also associated with increased risk for depressive disorders, but not anxiety disorders. Female subjects were more likely to have major depression than male participants (26% vs 7%). They were also much more likely than their male counterparts to have any type of depressive disorder (37% vs 10%).
The study also showed subjects with major depression or any depressive disorders were older than those without any type of depression.
Adolescents with psychiatric comorbidities did not consult clinicians more frequently or take more days of sick leave than those without psychiatric conditions.
This unexpected finding, the authors note, may result from ignorance among study subjects and their parents of psychiatric problems. As a result, clinicians need to screen for psychiatric comorbidity when assessing their young CDH patients, the authors comment.
Neurology. 2007;68:1468-1473.
According to the authors of the current study, CDH is a group of disorders in which headache occurs 15 or more days per month for at least 3 months, with subtypes such as chronic migraine, chronic tension-type headache, hemicrania continua, medication-overuse headache, and new and persistent daily headache as classified by the International Classification of Headache Disorders, second edition. Patients with migraines, especially with aura, have been reported to have a high risk for psychiatric comorbidities and suicide risk, which may be related to serotonergic dysfunction, and both can predict poorer outcome and quality of life.
This is a cross-sectional study of community-based adolescents from public schools in 1 country to determine the association between CDH and psychiatric comorbidities and suicide risk.